Life Sciences
JP Morgan 2023 – Raj Chopra
On the sidelines of JP Morgan 2023, pharmaphorum editor-in-chief Jonah Comstock sat down with Raj Chopra, acting CEO
The post JP Morgan 2023 – Raj Chopra…
On the sidelines of JP Morgan 2023, pharmaphorum editor-in-chief Jonah Comstock sat down with Raj Chopra, acting CEO of Aethon Therapeutics. Aethon recently launched January 9th, with $30 million in funding as a collaboration between Apple Tree Partners and NYU Langone Health.
In this interview, Chopra describes the HapImmune technology behind the company, which uses customised antibodies to create covalent inhibitors that bind to target proteins to create a peptide conjugate “beacon” that only shines on the surface of cancer cells, not healthy cells. This could be a major step forward for immuno-oncology therapy, or, as Chopra puts it, “another pillar in our armamentarium against cancer”.
They discuss how the different treatment modalities emerging against cancer will work together to deliver the true promise of precision medicine. Chopra also talks a little bit about plans so far for the future of Aethon.
View the video below and stay tuned for more live chats from JP Morgan Week.
The post JP Morgan 2023 – Raj Chopra appeared first on .
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….